Everything below concerns BPC-157. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Worldwide or global organizations: Generally open to nations worldwide as long as certain criteria are met. This category includes the United Nations and its specialized agencies, World Health Organization, International Telecommunication Union, World Bank, and International Monetary Fund. It also includes globally operating intergovernmental organizations that are not an agency of the UN, including for example: the Hague Conference on Private International Law, an operating intergovernmental organization based in The Hague that pursues the progressive unification of private international law; the International Criminal Court that adjudicates crimes defined under the Rome Statute; and the CGIAR (formerly the Consultative Group for International Agricultural Research), a global partnership that unites intergovernmental organizations engaged in research for a food-secured future. Cultural, linguistic, ethnic, religious or historical organizations: Open to members based on some cultural, linguistic, ethnic, religious or historical link. Examples include the Commonwealth of Nations, Arab League, Organisation internationale de la Francophonie, Community of Portuguese Language Countries, Organization of Turkic States, International Organization of Turkic Culture, Organisation of Islamic Cooperation, and Commonwealth of Independent States (CIS). Economic organizations: Based on macro-economic policy goals. Some are dedicated to free trade and reduction of trade barriers, e.g. World Trade Organization, International Monetary Fund. Others are focused on international development.
On 30 September 1846, Morton administered diethyl ether to Eben Frost, a music teacher from Boston, for a dental extraction. Two weeks later, Morton became the first to publicly demonstrate the use of diethyl ether as a general anesthetic at Massachusetts General Hospital, in what is known today as the Ether Dome. On 16 October 1846, John Collins Warren removed a tumor from the neck of a local printer, Edward Gilbert Abbott. Upon completion of the procedure, Warren reportedly quipped, "Gentlemen, this is no humbug." News of this event rapidly traveled around the world. Robert Liston performed the first amputation in December of that year. Morton published his experience soon after. Harvard University professor Charles Thomas Jackson (1805–1880) later claimed that Morton stole his idea; Morton disagreed and a lifelong dispute began. For many years, Morton was credited as being the pioneer of general anesthesia in the Western hemisphere, despite the fact that his demonstration occurred four years after Long's initial experience. Long later petitioned William Crosby Dawson (1798–1856), a United States Senator from Georgia at that time, to support his claim on the floor of the United States Senate as the first to use ether anesthesia. In 1847, Scottish obstetrician James Young Simpson (1811–1870) of Edinburgh was the first to use chloroform as a general anesthetic on a human (Robert Mortimer Glover had written on this possibility in 1842 but only used it on dogs). The use of chloroform anesthesia expanded rapidly thereafter in Europe.
Twelve-tone technique alone is nothing but the principle of motivic elaboration and variation, as developed in the sonata, but elevated now to a comprehensive principle of construction, namely transformed into an a priori form and, by that token, detached from the surface of the composition. At this point Adorno reversed his earlier priorities: now his musical activities came second to the development of a philosophical theory of aesthetics. Thus, in the middle of 1929, he accepted Paul Tillich's offer to present a habilitation on Kierkegaard, which Adorno eventually submitted under the title The Construction of the Aesthetic. At the time, Kierkegaard's philosophy exerted a strong influence, chiefly through its claim to pose an alternative to Idealism and Hegel's philosophy of history. Yet when Adorno turned his attention to Kierkegaard, watchwords like "anxiety," "inwardness," and "leap"—instructive for existentialist philosophy—were detached from their theological origins and posed, instead, as problems for aesthetics. As the work proceeded—and Kierkegaard's overcoming of Hegel's idealism was revealed to be a mere interiorization—Adorno excitedly remarked in a letter to Berg that he was writing without looking over his shoulder at the faculty who would soon evaluate his work. Receiving favorable reports from Professors Tillich and Horkheimer, as well as Benjamin and Kracauer, the university conferred on Adorno the venia legendi in February 1931. On the very day his revised study was published, 23 March 1933, Hitler seized dictatorial powers.
Inhibitors of GSSG binding, or dimerization: Reactive electrophiles such as gold compounds, and fluoronaphthoquinones. Drugs which use glutathione reductase to regenerate, such as redox cyclers. Two examples of these types of compounds are Methylene blue and Naphthoquinone. Clinical trials performed in Burkina Faso have revealed mixed results when treating malaria with Naphthoquinones In cells exposed to high levels of oxidative stress, like red blood cells, up to 10% of the glucose consumption may be directed to the pentose phosphate pathway (PPP) for production of the NADPH needed for this reaction. In the case of erythrocytes, if the PPP is non-functional, then the oxidative stress in the cell will lead to cell lysis and anemia. Lupus is an autoimmune disorder in which patients produce an elevated quantity of antibodies that attack DNA and other cell components. In a recent study, a single nucleotide polymorphism (SNP) in the Glutathione Reductase gene was found to be highly associated with lupus in African Americans in the study. African Americans with lupus have also been shown to express less reduced glutathione in their T cells. The study's authors believe that reduced glutathione reductase activity may contribute to the increased production of reactive oxygen in African Americans with lupus. In mice, glutathione reductase has been implicated in the oxidative burst, a component of the immune response.
=== Contraindications === Pregnancy is an absolute contraindication as with most other vitamin A products, it should also be avoided when it comes to systemic use in any women that is of childbearing potential and not taking precautions to prevent pregnancy. Toctino (the oral capsule formulation of alitretinoin) contains soya oil and sorbitol. Patients who are allergic to peanut, soya or with rare hereditary fructose intolerance should not take this medicine. It is also contraindicated in nursing mothers. The oral formulation of alitretinoin is contraindicated in patients with:
Sources: en.wikipedia.org
=== Keratinization of sulcular epithelium === Although the inherent nature of the sulcular epithelium is non-keratinised, studies have discovered the potentiality of sulcular epithelium to keratinise under certain environmental conditions. It was shown that when exposed to the environment of the gingival surface, the sulcular epithelium develops into a keratinised squamous epithelium similar to that on the regular outer surface of the gingiva.
== See also == Antimicrobial stewardship – Optimizing use of antimicrobials Blood management – Set of medical practicesPages displaying short descriptions of redirect targets Clinical decision support – Health information technologyPages displaying short descriptions of redirect targets Diagnostic stewardship – Optimizing use of medical diagnostic tests Laboratory medicine – Principles of management with special reference to medical sciencePages displaying short descriptions of redirect targets Quality management – Business process to aid consistent product fitness
Mealworms are typically used as a pet food for captive reptiles, fish, birds, and some small mammals. They are also provided to wild birds in bird feeders, particularly during the nesting season. Mealworms are useful for their high protein content. They are also used as fishing bait. They are commercially available in bulk and are typically available in containers with bran or oatmeal for food. Commercial growers incorporate a juvenile hormone into the feeding process to keep the mealworm in the larval stage and achieve an abnormal length of 2 cm or greater.
However, unique cultural-specific phenotypes of disordered eating emerged prior to Western influence. For example, restrictive eating patterns were found in Japan as early as the 18th century and fewer reports of eating disorders were found between 1868 and 1944, when rapid Westernization occurred. Sex-specific stressors and cultural dynamics could be implicated in this independent development of anorexia nervosa symptomology.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.